NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis

NICE gives negative guidance on Janssen’s Stelara for psoriatic arthritis


US health care giant Johnson & Johnson subsidiary Janssen today received a negative opinion from UK watchdog…

DermatologicalsInflammatory diseasesJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelaraUK

Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis


New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Four medicines recommended for approval by EMA/CHMP

Four medicines recommended for approval by EMA/CHMP


Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products…

AlconAntibiotics and Infectious diseasesComtriqDermatologicalsEuropeGaldermaJanssen-CilagJohnson & JohnsonMirvasoNovartisOncologyOphthalmicsPharmaceuticalRegulationSirturoTMC Pharma Services

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Janssen files NDA with FDA for canagliflozin in type 2 diabetes


Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Valeant to acquire J&J’s Ortho Dermatologics for $345 million


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an…

DermatologicalsJohnson & JohnsonMergers & AcquisitionsOrtho-McNeil-JanssenPharmaceuticalValeant Pharmaceuticals

EMEA recommends Janssen-Cilag’s Regranex not be used in patients with any pre-existing cancer


Following a review of the available data on a possible risk of cancer in patients using Regranex (becaplermin),…

BecaplerminDermatologicalsEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegranexRegulation

Back to top